RenovoRx (RNXT) Company Report

RenovoRx, Inc. announced that new clinical data supporting its TAMP therapy platform and RenovoCath drug-delivery device will be presented at the 2026 Society of Interventional Oncology (SIO) Annual Scientific Meeting on February 6, 2026.
The study's findings indicate that real-time intra-arterial pressure measurements during TAMP procedures are reliable and reproducible, suggesting opportunities for optimizing targeted chemotherapy delivery in solid tumors.
For the first nine months of 2025, RenovoRx generated approximately $900,000 of revenues from RenovoCath sales, with initial commercial purchase orders received in December 2024 and repeat orders from customers.
The company is also evaluating a novel drug-device combination oncology product candidate (IAG) in an ongoing Phase III trial, which has received Orphan Drug Designation for pancreatic and bile duct cancer, offering seven years of market exclusivity upon FDA approval.

3 days ago

Press Release

RenovoRx Expands RenovoCath Commercial Adoption to Nine Cancer Centers

RNXT

Product Launch

Revenue Acceleration/Inflection

New Projects/Investments

RenovoRx announced continued commercial momentum for its RenovoCath device, with the number of active commercial cancer centers integrating the device increasing from five in September 2025 to nine currently.
The new additions to the active commercial cancer centers include City of Hope Cancer Center in Duarte, California, and Moffitt Cancer Center in Tampa, Florida.
Through September 2025, RenovoRx generated approximately $900,000 in sales revenue from RenovoCath sales.
The company strengthened its go-to-market strategy by establishing a dedicated commercial team by the end of 2025, with the aim of achieving revenue growth in 2026 for RenovoCath as a standalone device.

Jan 20, 2026, 1:30 PM

Press Release

RenovoRx CEO to Participate in AlphaNorth Capital Event

RNXT

New Projects/Investments

Product Launch

RenovoRx, Inc. (Nasdaq: RNXT) CEO Shaun Bagai will participate in the AlphaNorth Capital Event from January 16-18, 2026, to provide a company update.
The update will cover the commercial progress of the FDA-cleared RenovoCath® drug-delivery device, noting increasing demand and adoption by new and returning customers, including top cancer centers.
Mr. Bagai will also discuss the ongoing Phase III TIGeR-PaC clinical trial evaluating intra-arterial gemcitabine (IAG) for locally advanced pancreatic cancer and the post-marketing observational registry.
RenovoRx announced its first commercial purchase orders for RenovoCath devices in December 2024, with repeat orders and new institutional adoptions expanding since.

Jan 14, 2026, 1:30 PM

Press Release

RenovoRx Presents Positive Clinical Data for TAMP Therapy Platform and Reports RenovoCath Sales

RNXT

New Projects/Investments

Product Launch

RenovoRx announced the presentation of new pharmacokinetic (PK) and pharmacodynamic data from a sub-study of its Phase III TIGeR-PaC clinical trial at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2026 (ASCO GI).
The data indicates that its Trans-Arterial Micro-Perfusion (TAMP) therapy platform, using intra-arterial gemcitabine (IAG), resulted in reduced systemic levels of gemcitabine and increased levels of its inactive metabolite compared to IV gemcitabine, suggesting potential for improved clinical efficacy and decreased side effects for locally advanced pancreatic cancer (LAPC).
The company generated approximately $900,000 in revenues from RenovoCath sales for the first nine months of 2025, actively commercializing the FDA-cleared device.
The IAG combination product candidate is currently under investigation and has not been approved for commercial sale, but has received Orphan Drug Designation for pancreatic cancer and bile duct cancer.

Jan 8, 2026, 1:30 PM

Press Release

RenovoRx Announces Clinical Data Abstract Acceptance for ASCO GI 2026

RNXT

New Projects/Investments

Product Launch

Revenue Acceleration/Inflection

RenovoRx's abstract on a sub-study of its Phase III TIGeR-PaC clinical trial has been accepted for presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026.
The sub-study, comparing intra-arterial gemcitabine (IAG) delivered by RenovoCath to intravenous gemcitabine for locally advanced pancreatic cancer, indicates decreased systemic drug levels with IAG, suggesting a potentially reduced clinical side effect profile.
The company reported generating approximately $900,000 in revenues from RenovoCath sales for the first nine months of 2025, following initial commercial purchase orders in December 2024.
The investigational drug-device combination product candidate (IAG) has received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which could provide seven years of market exclusivity upon FDA approval.

Dec 11, 2025, 1:30 PM

Press Release

RenovoRx Reports Q3 2025 Revenue and Clinical Trial Progress

RNXT

Revenue Acceleration/Inflection

Product Launch

New Projects/Investments

RenovoRx Inc. initiated commercialization of its FDA-cleared RenovoCath device in 2025, generating $900,000 in year-to-date revenue through Q3 2025 without a full sales infrastructure. The company anticipates ramping revenue growth in 2026 with a newly established sales team, targeting a peak U.S. market of over $400 million for the device alone.
The pivotal phase III TIGeR-PaC study for locally advanced pancreatic cancer is expected to complete enrollment early 2026, with final data anticipated in 2027. Early data from the trial showed a six-month survival benefit and 65% fewer toxicities.
The company reported over $10 million in cash at the end of Q3 2025. With a current cash burn of approximately $800,000 per month, the company projects its runway to extend into mid-2026. Device sales currently achieve 80% margins.

Dec 9, 2025, 5:30 PM

Transcript

RenovoRx Inc. Reports Q3 2025 Revenue and Provides Clinical Trial Update

RNXT

Revenue Acceleration/Inflection

New Projects/Investments

Guidance Update

RenovoRx Inc. reported $900,000 in year-to-date revenue through Q3 2025 from the commercialization of its FDA-cleared RenovoCath device, achieved without a dedicated sales infrastructure. The company projects a peak market of over $400 million for the device alone in the U.S. and expects growing revenues in 2026.
The company is progressing its pivotal Phase III TIGeR-PaC study for a drug-device combination in locally advanced pancreatic cancer, with enrollment expected to complete in early 2026 and final data anticipated in 2027.
Early data from the Phase III trial indicated a six-month survival benefit and a 65% reduction in toxicity profile compared to standard of care.
As of Q3 2025, RenovoRx held over $10 million in cash, with an estimated monthly burn of $800,000, providing a runway into at least mid-2026. Device sales currently have 80% margins.

Dec 9, 2025, 5:30 PM

Transcript

RenovoRx Reports Q3 2025 RenovoCath Revenue and Provides Clinical Trial Updates

RNXT

Product Launch

Guidance Update

Revenue Acceleration/Inflection

RenovoRx (RNXT) generated $900,000 in revenue from its FDA-cleared RenovoCath device by the end of Q3 2025, with an estimated $400 million potential peak sales for the device alone.
The company is expanding its sales and marketing team, with a Senior Director of Sales and Market Development hired in Q3 2025 and a Marketing Director joining in December 2025, to accelerate commercialization efforts for RenovoCath.
The Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer is expected to complete enrollment early 2026 and deliver final data in 2027, following an interim analysis that indicated a six-month survival benefit and a 65% reduction in systemic toxicities.
RenovoRx reported $10 million in cash at the end of Q3 2025 and a monthly cash burn of $800,000 for the quarter, with anticipated revenue growth from RenovoCath expected to reduce the burn and fund ongoing operations and trial completion.

Nov 20, 2025, 7:00 PM

Transcript

RenovoRx Discusses RenovoCath Revenue and TIGeR-PaC Trial Interim Results

RNXT

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

RenovoRx reported $900,000 in RenovoCath revenue through the end of Q3 2025, achieved without a dedicated sales and marketing infrastructure, and anticipates $400 million in potential peak sales for the device alone.
The company finished Q3 2025 with $10 million in cash and a monthly burn rate of $800,000.
The Phase III TIGeR-PaC clinical trial for locally advanced pancreatic cancer is anticipated to complete enrollment early next year (2026) with final data expected in 2027.
An interim analysis of the Phase III trial showed a six-month survival benefit, with patients living 21.5 months compared to 15.5 months for the control arm, and a 65% reduction in systemic toxicities.
RenovoRx is actively building its sales team for 2026 and aims to reach 25-50 hospitals using the device to generate over $1 million in monthly revenue to cover its burn, leveraging the device's 80% margin.

Nov 20, 2025, 7:00 PM

Transcript

RenovoRx Provides Business Update and Financial Highlights

RNXT

Product Launch

Revenue Acceleration/Inflection

New Projects/Investments

RenovoRx (RNXT) reported $900,000 in revenue from its FDA-cleared RenovoCath device through the end of Q3 2025. The company anticipates $400 million in potential peak sales for the device alone, which has an 80% margin.
The company finished Q3 2025 with $10 million in cash and a cash burn of $800,000 per month. RenovoRx is expanding its sales and marketing team to accelerate commercialization of RenovoCath.
The phase III clinical trial for its drug-device combination in locally advanced pancreatic cancer is anticipated to complete enrollment early 2026, with final data expected in 2027. An interim analysis showed a six-month survival benefit and a 65% reduction in systemic toxicities.